Mono(2-ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxohexyl) phthalate as biomarkers for human exposure assessment to di-(2-ethylhexyl) phthalate. by Kato, Kayoko et al.
Di-(2-ethylhexyl) phthalate (DEHP), one of
the most widely used phthalates, is a primary
component in polyvinyl chloride plastics used
in numerous household products, toys, ﬂoor
tiles, furniture upholstery, blood storage bags,
and medical devices, among other products
[Agency for Toxic Substances and Disease
Registry (ATSDR) 2002; Faouzi et al. 1999].
Therefore, the potential for human exposure
to DEHP is high. DEHP is not chemically
bound in the plastics; hence, it can be leached
to the environment during the manufacturing
process and product use and after disposal
(ATSDR 2002; Sharman et al. 1994). The
general population is exposed to DEHP in
food, water, and air through inhalation and
ingestion (ATSDR 2002; Meek and Chan
1994; Sharman et al. 1994). Medical patients
receiving transfusions (Peck et al. 1979) or
dialysis (Faouzi et al. 1999) or those undergo-
ing apheresis may be more exposed to DEHP
than the general population (Ono et al.
1975). DEHP is not classiﬁable as to its car-
cinogenicity to humans by the International
Agency for Research on Cancer (IARC
2000), but it has been designated a carcino-
gen in experimental animals (IARC 2000;
Kluwe et al. 1982). Moreover, results from
animal toxicologic studies have demonstrated
endocrine-modulating effects from high doses
of DEHP (Gray et al. 1999). DEHP alters
thyroid structure and activity (Gray et al.
1999; Hinton et al. 1986) in male Wistar rats
and produces reproductive and developmen-
tal toxicities in rodents (Kavlock et al. 2002).
In male rodents, the testes are a primary tar-
get tissue, and exposure to high doses of
DEHP results in decreased testicular weights
and tubular atrophy (ATSDR 2002).
Metabolism of DEHP involves hydrolysis
to mono(2-ethylhexyl) phthalate (MEHP) and
formation of a glucuronide MEHP conjugate.
The glucuronide conjugate and the free
monoester can be excreted in urine and feces
or, alternatively, can undergo ω or (ω-1)
hydroxylation or β elimination to form several
oxidative metabolites (Albro et al. 1973;
ATSDR 2002). These oxidative metabolites
can also be excreted in urine and feces as the
free monoester or glucuronide conjugates.
Several methods of measuring DEHP in
biologic matrices have been published (Albro
et al. 1984; Luster et al. 1978). However,
because DEHP is a ubiquitous laboratory con-
taminant, field blanks show concentrations
similar to those in the matrices under study,
thus limiting the accuracy of the measure-
ments. Measuring metabolites instead of the
parent phthalate overcomes this limitation and
makes accurate exposure assessment possible
(Blount et al. 2000a; Kato et al. 2003; Silva
et al. 2003a). We have used urinary MEHP
measurements in our previous studies for expo-
sure assessment of DEHP [Blount et al.
2000b; Brock et al. 2002; Centers for Disease
Control and Prevention (CDC) 2003].
However, the concentrations of MEHP we
found in human urine were lower than those
of other phthalate monoesters, particularly the
phthalates with fewer carbons in the alkyl side
chains, despite the likely higher availability of
DEHP. This could result from several factors,
including differences in exposure, systemic
absorption from the gastrointestinal tract
(White et al. 1980), metabolism (Albro and
Moore 1974; Williams and Blanchﬁeld 1974,
1975), and excretion. Phthalates with short
alkyl side chains undergo oxidative metabolism
to a lesser extent (Albro and Moore 1974;
Williams and Blanchﬁeld 1974, 1975), com-
pared with phthalates with long alkyl side
chains. The differences in metabolism among
phthalates could result in urinary excretion of
comparatively higher levels of the monoester
metabolites of the phthalates with short alkyl
chains than for DEHP, which is initially
metabolized to MEHP and then further to sev-
eral oxidative metabolites (Albro et al. 1973;
ATSDR 2002).
Although concentrations in urine samples
provide invaluable exposure information, the
concentrations of excreted substances are
dependent on water intake. Therefore, toxi-
cokinetics are easier to interpret from mea-
surements in blood (e.g., serum, plasma), and
serum markers of DEHP exposure might
prove more useful. However, we recently
have shown that blood measurements of
phthalate monoesters are susceptible to conta-
mination from the parent phthalates, which
are hydrolyzed to their respective monoesters
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Exposure to di-(2-ethylhexyl) phthalate (DEHP) is prevalent based on the measurement of its
hydrolytic metabolite mono-(2-ethylhexyl) phthalate (MEHP) in the urine of 78% of the general
U.S. population studied in the 1999–2000 National Health and Nutrition Examination Survey
(NHANES). However, despite the high level of production and use of DEHP, the urinary MEHP
levels in the NHANES samples were lower than the monoester metabolites of phthalates less com-
monly used than DEHP, suggesting metabolic differences between phthalates. We measured
MEHP and two oxidative DEHP metabolites, mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP)
and mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) to verify whether these other metabo-
lites account for a greater proportion of DEHP metabolic products in 127 paired human urine
and serum samples. We found that the urinary levels of MEHHP and MEOHP were 10-fold
higher than levels of MEHP; concentrations of urinary MEOHP and MEHHP were strongly cor-
related (r = 0.928). We also found that the serum levels of MEOHP and MEHHP were compara-
tively lower than those in urine. Furthermore, the glucuronide-bound conjugates of the oxidative
metabolites were the predominant form in both urine and serum. MEOHP and MEHHP cannot
be formed by serum enzymes from the hydrolysis of any contamination from DEHP potentially
introduced during blood collection and storage. Therefore, concentrations of MEHHP and
MEOHP in serum may be a more selective measure of DEHP exposure than is MEHP. However,
additional data on the absorption, distribution, metabolism, and elimination of these oxidative
metabolites are needed to completely understand the extent of DEHP exposure from the serum
concentrations of oxidative DEHP metabolites. Key words: DEHP, MEHHP, MEHP, MEOHP,
phthalate metabolites, phthalates. Environ Health Perspect 112:327–330 (2004).
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contamination is not properly eliminated, the
measured concentrations in serum of the
phthalate monoesters, but not of the oxidative
metabolites, will be artiﬁcially elevated.
To address these problems, we evaluated
MEHP and two oxidative metabolites, mono-
(2-ethyl-5-oxohexyl) phthalate (MEOHP) and
mono-(2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP), as markers for exposure to DEHP
in 127 paired human urine and serum samples.
Materials and Methods
MEHHP, MEOHP, MEHP (Figure 1),
DEHP, 13C4-monobutyl phthalate (13C4-
mBP), 13C4-MEHP, and 13C4-4-methyl-
umbelliferone (13C4-MeUmb) were purchased
from Cambridge Isotopes Laboratories Inc.
(Andover, MA, USA). Acetonitrile and water
(HPLC grade) were purchased from Tedia
(Fairfield, OH, USA), MeUmb and its glu-
curonide (MeUmb-glu) were purchased
from Sigma Chemical Co. (St. Louis, MO,
USA). β-Glucuronidase (Escherichia coli-
K12) was purchased from Roche Biomedical
(Mannheim, Germany). Stock solutions of
standards (MEHP, MEOHP, MEHHP, and
MeUmb) and internal standards (13C4-mBP,
13C4-MEHP, and 13C4-MeUmb) were pre-
pared in acetonitrile (Blount et al. 2000a). The
internal standard spiking solution consisted of
13C4-mBP (20 ng) and 13C4-MEHP (12 ng).
13C4-mBP was used as the internal standard
for MEOHP and MEHHP because of their
similar retention on the HPLC column.
13C4-MEHP was used as the internal standard
for MEHP.
High (~200 ng/mL) and low (~25 ng/mL)
quality control (QC) pools were prepared
from split pooled human urine and bovine
serum. The urine and serum were spiked with
the desired amounts of MEOHP, MEHHP,
MEHP, and phosphoric acid (only the serum
pools), mixed well, and divided into aliquots.
A reagent blank and one each of the concen-
trations of QC materials were analyzed during
each analytical run to ensure proper operation
of the method and the validity of the resulting
data.
To determine the effect of serum lipases on
MEHP, MEHHP, and MEOHP levels,
DEHP-spiked (2,000 ng/mL) serum aliquots
(1 mL) were incubated at 37°C. We then mea-
sured the concentrations of MEHP, MEHHP,
and MEOHP in the DEHP-spiked serum after
adding phosphoric acid (Kato et al. 2003) at
different time intervals to evaluate the effect of
the acid on the enzyme activity.
The analytical methods for measuring
phthalate metabolites in urine and serum were
adapted from our previously developed meth-
ods and modified to meet our requirements
for the analysis of MEOHP and MEHHP
(Blount et al. 2000a; Kato et al. 2003; Silva
et al. 2003a). For the free metabolite (non-
glucuronidated) analysis, the β-glucuronidase
enzyme treatment for both unknown sam-
ples and QC materials was eliminated. The
urine and serum samples (1 mL) were spiked
with 13C4-labeled internal standards and
MeUmb-glu (to evaluate the completion of
the hydrolysis), and the phthalate metabolites
were extracted from the matrix by solid-phase
extraction. The ﬁnal eluate was concentrated
and resuspended in water. The analytes were
chromatographically separated (HP 1100,
Agilent Technologies, Wilmington, DE,
USA) on a Keystone phenyl Betasil column
(Keystone Scientific, Bellefonte, PA, USA)
using a nonlinear water:acetonitrile gradient
and analyzed by tandem mass spectrometry on
an API 3000 (Applied Biosystems, Foster
City, CA, USA) using electrospray ionization.
The limits of detection (LODs) were calcu-
lated as 3S0, where S0 is the standard deviation
value as the concentration approaches zero
(Taylor 1987). S0 was determined from the
replicate analysis of low-level standards. The
relative standard deviations ranged from 8%
to 13%. The LODs in urine were 1.2 ng/mL
(MEOHP), 1.6 ng/mL (MEHHP), and
0.9 ng/mL (MEHP) (Silva et al. 2003a); the
LODs in serum were 1.3 ng/mL (MEHP)
(Kato et al. 2003), 1.4 ng/mL (MEOHP),
and 1.9 ng/mL (MEHHP).
All of the samples, blanks, standards, and
QC materials were processed identically using
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Table 1. The urinary and serum levels (ng/mL) of MEHP, MEOHP, and MEHHP in a group of 127 persons.
Phthalate Percentage Selected percentiles
monoester Matrix detects GMa 5th 25th 50th 75th 95th
MEHP
Total Urine 35 ND < LOD < LOD < LOD 2.3 20.4
Serumb 88 3.9 < LOD 2.8 4.0 5.9 15.2
Free Urine 1 ND < LOD < LOD < LOD < LOD < LOD
Serumb 84 2.5 < LOD 2.2 2.8 3.4 5.0
MEOHP
Total Urine 91 14.8 <  LOD 5.1 15.6 40.1 243
Serum 18 ND < LOD < LOD < LOD < LOD 3.4
Free Urine 62 5.6 < LOD 1.3 3.9 9.6 48.8
Serum 3 ND < LOD < LOD < LOD < LOD < LOD
MEHHP
Total Urine 95 19.3 < LOD 8.8 17.4 41.1 220
Serum 44 ND < LOD < LOD < LOD < LOD 3.1
Free Urine 38 ND < LOD < LOD < LOD < LOD 5.8
Serum 4 ND < LOD < LOD < LOD < LOD < LOD
Abbreviations: GM, geometric mean; ND, not determined (geometric means were determined only when the frequency of
detection was ≥ 60%).
aLOD/√– 2 was used if the concentration was < LOD. bConcentrations may be artiﬁcially overestimated because of serum
lipase activity.
Figure 1. DEHP metabolites used as markers of human exposure to DEHP.
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Figure 2. Pearson correlation analyses between
the concentrations of urinary MEHHP and MEOHP
(r = 0.928, p < 0.0001).
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Figure 3. Correlation between urinary MEHP and
MEHHP (r = 0.892) and urinary MEHP and MEOHP
(r = 0.878).
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▲the Analyst software (Applied Biosystems) of
the API 3000. Each ion of interest in the chro-
matogram was automatically selected and inte-
grated. The peak integrations were checked for
errors and corrected manually, if necessary.
A calibration curve of peak area ratio of ana-
lyte to 13C-labeled internal standard peak area
ratio (after compensating for isotopic impurity
of labeled internal standard) versus the recip-
rocal of concentration (1/x) was used for
quantiﬁcation. Samples with values below the
LODs were assigned a concentration equal to
the LOD divided by the square root of 2 for
the statistical analyses. The measured values
were used in the ﬁgures. Statistical signiﬁcance
was set at p < 0.05. Statistical analysis of the
data was performed using SAS software (SAS
Institute, Cary, NC, USA).
Subjects. The samples analyzed for this
study were collected from 176 U.S. residents
during 2001 from a demographically diverse
population group with no documented
exposure to DEHP; 127 were paired urine
and serum samples. The samples were col-
lected at different times throughout the day,
and the urine samples were not necessarily
ﬁrst-morning voids. Serum and urine samples
were collected on the same day. Informed
consent was obtained from all participants.
Results and Discussion
The concentrations of the three DEHP
metabolites MEHP, MEOHP, and MEHHP
varied widely among the samples tested.
Concentrations of MEOHP and MEHHP in
urine appeared approximately 10-fold higher
than the concentrations of MEHP (Table 1).
In addition, the urinary concentrations of
MEOHP and MEHHP were highly correlated
(Figure 2; r = 0.928, p < 0.0001), in agreement
with our previous ﬁndings (Barr et al. 2003).
We also observed a good correlation between
urinary MEHP and MEHHP levels (r = 0.892,
p < 0.0001) and between MEHP and
MEOHP levels (r = 0.878, p < 0.0001)
(Figure 3). The correlations did not improve
significantly after adjusting for creatinine to
correct for urine dilution (data not shown).
The oxidative metabolites may be glu-
curonidated in the body to increase their water
solubility, hence facilitating the urinary excre-
tion. Furthermore, glucuronidation is a major
mechanism for elimination of the potentially
toxic MEHP (Silva et al. 2003b). In this
study, 81% of the participants excreted > 95%
urinary MEHHP in its glucuronidated form,
whereas 52% of the participants excreted
> 95% urinary MEOHP as the glucuronide
(Figure 4). These data suggest that MEOHP
and MEHHP are excreted in urine mainly in
their conjugated form. We also found a good
correlation between the free and total urinary
levels of the oxidative metabolites (Figure 5).
The fact that the levels of these metabolites in
their free form did not plateau suggests that
the saturation or inhibition of the enzyme cat-
alyzing the glucuronidation reaction did not
occur at the exposed concentrations.
We also quantiﬁed the levels of these same
DEHP metabolites in serum (Table 1). The
oxidative metabolites were detected in < 50%
of serum specimens. For specimens with
detectable concentrations of MEOHP and
MEHHP, the serum concentrations were
lower than the urinary concentrations
(Table 1). The lower levels in serum compared
with those in urine for nonpersistent com-
pounds, including the phthalate metabolites,
are common (Barr et al. 1999, 2002; Silva
et al. 2003b). Interestingly, the percentage of
samples with detectable levels of free MEOHP
and MEHHP in serum was much lower than
for total MEOHP and MEHHP, suggesting
serum MEOHP and MEHHP were found
predominantly in their glucuronidated forms.
We previously reported (Kato et al. 2003)
that a treatment of the serum samples with
acid was required at sample collection to dena-
ture serum enzymes that convert the phthalate
diesters (also present in the sample as a result
of contamination) to their respective hydro-
lytic monoester metabolites. The serum sam-
ples analyzed for this study were archived
samples. We made no attempt to eliminate the
lipase activity that might have falsely elevated
the serum MEHP levels from hydrolysis of
DEHP by serum lipases (Kato et al. 2003) if
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Figure 4. Frequency of detection of free urinary MEHHP and MEOHP.
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Figure 5. Pearson correlation analyses (A) between the concentrations of total and free urinary MEHHP
(r = 0.792, p < 0.0001) and (B) between total and free urinary MEOHP (r = 0.821, p < 0.0001).
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Figure 6. Concentrations of MEHP, MEHHP, and
MEOHP in serum at different time intervals after
spiking with 2,000 ng/mL DEHP. The error bars rep-
resent the SD of triplicate measurements. The con-
centration of MEHP in DEHP-spiked serum samples
increased with time, whereas the concentrations of
MEOHP and MEHHP remained unchanged.
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■preanalytical DEHP contamination of the
samples had occurred. Therefore, the levels of
MEHP reported in the present study include
an unknown contribution from the monoester
formed from the lipase-induced hydrolysis of
possible contaminant DEHP incorporated in
the specimen during the sampling process
(Table 1). Because the oxidative phthalate
metabolites cannot be formed from the enzy-
matic cleavage of DEHP, their measurements
in serum are not affected by DEHP contami-
nation (Figure 6). Consequently, serum mea-
surements of MEOHP and MEHHP would
not be overestimated, even in the presence of
high levels of contaminant DEHP. However,
to maximize the utility of serum MEOHP
and MEHHP as markers of exposure to low
levels of DEHP, improvement of the sensitiv-
ity of the serum analytical measurements
would be necessary.
We observed an association between the
levels of MEHHP and MEOHP in urine and
serum (p < 0.001). The serum MEHHP and
MEOHP levels tended to increase with
increasing urinary concentrations (Figure 7).
Unlike in urine, in serum MEHP was found
more often than MEHHP or MEOHP.
Because the lipase activity in serum was not
eliminated, the MEHP measurements should
be interpreted with caution. Additional stud-
ies where the serum lipase activity is elimi-
nated should be conducted to determine if
this ﬁnding is an artifact of contamination.
In summary, our data suggest that
MEHHP and MEOHP are excreted in the
urine predominantly as glucuronide conjugates
and at higher concentrations than MEHP. The
higher frequency of detection of MEOHP and
MEHHP than of MEHP in urine and the fact
that the urinary levels of MEOHP and
MEHHP were approximately 10-fold higher
than MEHP suggest that MEOHP and
MEHHP may be more sensitive urinary mark-
ers of DEHP exposure and may allow low-level
exposures to be more readily detected.
However, because MEHP is believed to be
responsible for the biologic activity attributed
to DEHP exposure, MEHP measurements
may be more relevant in studies investigating
associations between DEHP exposure and
adverse health outcomes. Because no informa-
tion about the biologic activity of the oxidative
metabolites is available, further research to
establish the bioactivity of MEHHP and
MEOHP is warranted.
REFERENCES
Albro PW, Jordan S, Corbett JT, Schroeder JL. 1984.
Determination of total phthalate in urine by gas chromatog-
raphy. Anal Chem 56:247–250.
Albro PW, Moore B. 1974. Identiﬁcation of the metabolites of sim-
ple phthalate diesters in rat urine. J Chromatogr 94:209–218.
Albro PW, Thomas R, Fishbein L. 1973. Metabolism of diethyl-
hexyl phthalate by rats. Isolation and characterization of
the urinary metabolites. J Chromatogr 76:321–330.
ATSDR. 2002. Toxicological Proﬁle for Di(2-ethylhexyl)phthalate
(DEHP). Atlanta, GA:Agency for Toxic Substances and
Disease Registry. Available: http://www.atsdr.cdc.gov/
toxproﬁles/tp9.html [accessed 11 August 2003].
Barr DB, Barr JR, Driskell WJ, Hill RH, Ashley DL, Needham LL,
et al. 1999. Strategies for biological monitoring of exposure
for contemporary-use pesticides. Toxicol Ind Health
15:168–179.
Barr DB, Barr JR, Maggio VL, Whitehead RD, Sadowski MA,
Whyatt RM, et al. 2002. A multi-analyte method for the
quantiﬁcation of contemporary pesticides in human serum
and plasma using high-resolution mass spectrometry.
J Chromatogr B 778:99–111.
Barr DB, Silva MJ, Kato K, Reidy JA, Malek NA, Hurtz D, et al.
2003. Assessing human exposure to phthalates using
monoesters and their oxidized metabolites as biomarkers.
Environ Health Perspect 111:1148–1151.
Blount BC, Milgram KE, Silva MJ, Malek NA, Reidy JA, Needham
LL, et al. 2000a. Quantitative detection of eight phthalate
metabolites in human urine using HPLC-APCI-MS/MS. Anal
Chem 72:4127–4134.
Blount BC, Silva MJ, Caudill SP, Needham LL, Pirkle JL,
Sampson EJ, et al. 2000b. Levels of seven urinary phtha-
late metabolites in a human reference population. Environ
Health Perspect 108:979–982.
Brock JW, Caudill SP, Silva MJ, Needham LL, Hilborn ED. 2002.
Phthalate monoesters levels in the urine of young children.
Bull Environ Contam Toxicol 68:309–314.
CDC. 2003. Second National Report on Human Exposure to
Environmental Chemicals. Atlanta, GA:Centers for Disease
Control and Prevention. Available: http://www.cdc.gov/
exposurereport [accessed 11 August 2003].
Faouzi MA, Dine T, Gressier B, Kambia K, Luyckx M, Pagniez D,
et al. 1999. Exposure of hemodialysis patients to di-2-ethyl-
hexyl phthalate. Int J Pharm 180:113–121.
Gray LE, Wolf C, Lambright C, Mann P, Price M, Cooper RL, et al.
1999. Administration of potentially antiandrogenic pesti-
cides (procymidone, linuron, iprodione, chlozolinate,
p,p´-DDE, and ketoconazole) and toxic substances (dibutyl-
and diethylhexyl phthalate, PCB 169, and ethane dimethane
sulphonate) during sexual differentiation produces diverse
profiles of reproductive malformations in the male rat.
Toxicol Ind Health 15:94–118.
Hinton RH, Mitchell FE, Mann A, Chescoe D, Price SC, Nunn A,
et al. 1986. Effects of phthalic-acid esters on the liver and
thyroid. Environ Health Perspect 70:195–210.
IARC. 2000. Di(2-ehtylhexyl Phthalate (Group 3). IARC Monogr
Eval Carcinog Risk Hum 77:41–148. Available: http://
193.51.164.11/htdocs/monographs/vol77/77-01.html
[accessed 20 January 2004].
Kato K, Silva MJ, Brock JW, Reidy JA, Malek NA, Hodge CC,
et al. 2003. Quantitative detection of nine phthalate
metabolites in human serum using reversed-phase high-
performance liquid chromatography-electrospray ioniza-
tion-tandem mass spectrometry. J Anal Toxicol 27:284–289.
Kavlock R, Boekelheide K, Chapin R, Cunningham M, Faustman E,
Foster P, et al. 2002. NTP Center for the Evaluation of Risks to
Human Reproduction: phthalates expert panel report on the
reproductive and developmental toxicity of di(2-ethylhexyl)
phthalate. Reprod Toxicol 16:529–653.
Kluwe WM, McConnell EE, Huff JE, Haseman JK, Douglas JF,
Hartwell WV. 1982. Carcinogenicity testing of phthalate-
esters and related compounds by the National Toxicology
Program and the National Cancer Institute. Environ Health
Perspect 45:129–133.
Luster MI, Albro PW, Chae K, Clark G, McKinney JD. 1978.
Radioimmunoassay for mono-(2-ethylhexyl) phthalate in
unextracted plasma. Clin Chem 24:429–432.
Meek ME, Chan PKL. 1994. Bis(2-ethylhexyl)phthalate—evalua-
tion of risks to health from environmental exposure in
Canada. J Environ Sci Health Part C 12:179–194.
Ono K, Tatsukawa R, Wakimoto T. 1975. Migration of plasticizer
from hemodialysis blood tubing. Preliminary report. JAMA
234:948–949.
Peck CC, Odom DG, Friedman HI, Albro PW, Hass JR, Brady JT,
et al. 1979. Di-2-ethylhexyl phthalate (DEHP) and mono-2-
ethylexyl phthalate (MEHP) accumulation in whole blood
and red cell concentrates. Transfusion 19:137–146.
Sharman M, Read WA, Castle L, Gilbert J. 1994. Levels of di-(2-
ethylhexyl)phthalate and total phthalate-esters in milk,
cream, butter and cheese. Food Addit Contam 11:375–385.
Silva MJ, Barr DB, Reidy JA, Kato K, Malek NA, Hodge CC, et al.
2003b. Glucuronidation patterns of common urinary and
serum monoester phthalate metabolites. Arch Toxicol
77:561–567.
Silva MJ, Malek NA, Hodge CC, Reidy JA, Kato K, Barr DB, et al.
2003a. Improved quantitative detection of 11 urinary phtha-
late metabolites in humans using liquid chromatography-
atmospheric pressure chemical ionization tandem mass
spectrometry. J Chromatogr B 789:393–404.
Taylor JK. 1987. Quality Assurance of Chemical Measurements.
Chelsea, MI:Lewis Publishers.
White RD, Carter DE, Earnest D, Mueller J. 1980. Absorption
and metabolism of 3 phthalate diesters by the rat small-
intestine. Food Cosmet Toxicol 18:383–386.
Williams DT, Blanchfield BJ. 1974. Retention, excretion and
metabolism of di-(2-ethylhexyl) phthalate administered
orally to the rat. Bull Environ Contam Toxicol 11:371–378.
———. 1975. The retention, distribution, excretion, and metab-
olism of dibutyl phthalate-7-14 C in the rat. J Agric Food
Chem 23:854–858.
Article | Kato et al.
330 VOLUME 112 | NUMBER 3 | March 2004 • Environmental Health Perspectives
Figure 7. Pearson correlation analyses between the concentrations of (A) total urinary MEHHP and total serum
MEHHP (r= 0.796, p< 0.0001) and (B) total urinary MEOHP and total serum MEOHP (r= 0.615, p< 0.0001).
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